IMITREX tablet contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
IMITREX Tablets are contraindicated in patients with: | IMITREX Tablets are contraindicated in patients with: | ||
Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)] | * Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)] | ||
Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)] | * Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)] | ||
History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)] | * History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)] | ||
Peripheral vascular disease [see Warnings and Precautions (5.5)] | * Peripheral vascular disease [see Warnings and Precautions (5.5)] | ||
Ischemic bowel disease [see Warnings and Precautions (5.5)] | * Ischemic bowel disease [see Warnings and Precautions (5.5)] | ||
Uncontrolled hypertension [see Warnings and Precautions (5.8)] | * Uncontrolled hypertension [see Warnings and Precautions (5.8)] | ||
Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7.1, 7.3)] | * Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7.1, 7.3)] | ||
Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] | * Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] | ||
Hypersensitivity to IMITREX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] | * Hypersensitivity to IMITREX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] | ||
Severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = IMITREX (SUMATRIPTAN SUCCINATE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=584abe73-8290-4484-ff8e-5890831c095e | publisher = | date = | accessdate = }}</ref> | * Severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = IMITREX (SUMATRIPTAN SUCCINATE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=584abe73-8290-4484-ff8e-5890831c095e | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 07:50, 1 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
IMITREX Tablets are contraindicated in patients with:
- Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)]
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)]
- History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)]
- Peripheral vascular disease [see Warnings and Precautions (5.5)]
- Ischemic bowel disease [see Warnings and Precautions (5.5)]
- Uncontrolled hypertension [see Warnings and Precautions (5.8)]
- Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7.1, 7.3)]
- Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]
- Hypersensitivity to IMITREX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)]
- Severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)][1]
References
Adapted from the FDA Package Insert.